Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase
US8344008B2 · kind B2 · utility
4Cited by
7References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 21, 2011 |
| Grant date | Jan 1, 2013 |
| Priority date | — |
| Expiry date | Apr 21, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.